[go: up one dir, main page]

SG10201500350PA - 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition - Google Patents

15-valent pneumococcal polysaccharide-protein conjugate vaccine composition

Info

Publication number
SG10201500350PA
SG10201500350PA SG10201500350PA SG10201500350PA SG10201500350PA SG 10201500350P A SG10201500350P A SG 10201500350PA SG 10201500350P A SG10201500350P A SG 10201500350PA SG 10201500350P A SG10201500350P A SG 10201500350PA SG 10201500350P A SG10201500350P A SG 10201500350PA
Authority
SG
Singapore
Prior art keywords
vaccine composition
protein conjugate
conjugate vaccine
pneumococcal polysaccharide
valent pneumococcal
Prior art date
Application number
SG10201500350PA
Inventor
Michael J Caulfield
Patrick L Ahl
Jeffrey T Blue
Jayme L Cannon
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of SG10201500350PA publication Critical patent/SG10201500350PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201500350PA 2010-02-09 2011-02-03 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition SG10201500350PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30272610P 2010-02-09 2010-02-09

Publications (1)

Publication Number Publication Date
SG10201500350PA true SG10201500350PA (en) 2015-03-30

Family

ID=44353903

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201500350PA SG10201500350PA (en) 2010-02-09 2011-02-03 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
SG2012058236A SG183199A1 (en) 2010-02-09 2011-02-03 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012058236A SG183199A1 (en) 2010-02-09 2011-02-03 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition

Country Status (25)

Country Link
US (2) US8192746B2 (en)
EP (1) EP2533805A4 (en)
JP (2) JP2013518891A (en)
KR (1) KR101538535B1 (en)
CN (1) CN102858365A (en)
AR (2) AR080122A1 (en)
AU (1) AU2011216095B2 (en)
BR (1) BR112012019757B8 (en)
CA (1) CA2788680C (en)
CL (1) CL2012002195A1 (en)
EC (1) ECSP12012100A (en)
IL (1) IL221283A0 (en)
MA (1) MA34051B1 (en)
MX (1) MX2012009206A (en)
MY (1) MY159984A (en)
NZ (1) NZ601711A (en)
PE (1) PE20121698A1 (en)
PH (1) PH12012501559A1 (en)
RU (1) RU2012138368A (en)
SG (2) SG10201500350PA (en)
TN (1) TN2012000377A1 (en)
TW (1) TW201136603A (en)
UA (1) UA106115C2 (en)
WO (1) WO2011100151A1 (en)
ZA (1) ZA201205737B (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102611449B1 (en) 2005-04-08 2023-12-06 와이어쓰 엘엘씨 Multivalent pneumococcal polysaccharide-protein conjugate composition
ES2662651T3 (en) 2005-06-27 2018-04-09 Glaxosmithkline Biologicals S.A. Immunogenic composition
EA015964B1 (en) 2006-09-07 2012-01-30 Глаксосмитклайн Байолоджикалс С.А. Vaccine
ES2969952T3 (en) 2011-04-22 2024-05-23 Wyeth Llc Compositions related to a mutant Clostridium difficile toxin and their procedures
US9573811B2 (en) * 2011-11-23 2017-02-21 Merck Sharp & Dohme Corp. Method for preparation of aluminum hydroxyphosphate adjuvant
KR102057217B1 (en) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
BR122016023101B1 (en) 2012-10-21 2022-03-22 Pfizer Inc Polypeptide, immunogenic composition comprising it, as well as recombinant cell derived from Clostridium difficile
KR20140075201A (en) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
KR20140075196A (en) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
CN103495161B (en) * 2013-10-08 2019-06-18 江苏康泰生物医学技术有限公司 A kind of mixture and preparation method thereof of polynary pneumococcal capsular polysaccharide-protein conjugate
TWI586363B (en) * 2013-10-30 2017-06-11 Sk化學公司 Multivalent pneumococcal polysaccharide-protein conjugate composition
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR102049825B1 (en) 2014-01-21 2019-12-03 화이자 인코포레이티드 Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
EP3957321A3 (en) * 2014-01-21 2022-07-13 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
NZ760783A (en) * 2014-01-21 2023-07-28 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
ES2930318T3 (en) * 2014-02-14 2022-12-09 Pfizer Immunogenic glycoprotein conjugates
CN103893751B (en) * 2014-03-26 2016-04-20 天津康希诺生物技术有限公司 A kind of pneumococal polysaccharide Protein Conjugation vaccine and preparation method thereof
MX2017015985A (en) 2015-06-08 2018-08-15 Serum Inst Of India Private Ltd Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof.
RS61440B1 (en) * 2015-06-23 2021-03-31 Biological E Ltd Multivalent pneumococcal conjugate vaccine
JP6994453B2 (en) * 2015-07-21 2022-01-14 ファイザー・インク Immunogenic compositions containing conjugated capsule saccharide antigens, kits containing them and their use
MY177587A (en) 2015-09-10 2020-09-22 Inventprise Llc Multivalent vlp conjugates
WO2017173415A2 (en) 2016-03-31 2017-10-05 Liffey Biotech Limited Saccharide-polypeptide conjugate compositions and methods of use thereof
EP3481407A4 (en) * 2016-07-08 2020-04-01 Hawaii Biotech, Inc. VACCINE AGAINST THE WEST NIL VIRUS AND METHOD FOR USE THEREOF
PH12019500238B1 (en) 2016-08-05 2023-05-10 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
CA3031799A1 (en) * 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2017336806B2 (en) 2016-09-30 2024-06-27 Biological E Limited Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
KR102083973B1 (en) * 2016-10-28 2020-04-23 주식회사 엘지화학 A multivalent immunogenic composition with improved IgG titer and use thereof
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
AU2017388891C1 (en) 2016-12-30 2025-04-17 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
WO2018144439A1 (en) * 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
WO2018144438A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
US11246918B2 (en) 2017-02-03 2022-02-15 Eva Barbara Schadeck Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
BR112019017560A2 (en) 2017-02-24 2020-04-07 Merck Sharp & Dohme enhancement of immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates
JP7254707B2 (en) * 2017-02-24 2023-04-10 メルク・シャープ・アンド・ドーム・エルエルシー Pneumococcal conjugate vaccine formulation
US11400162B2 (en) 2017-02-24 2022-08-02 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
US11219680B2 (en) * 2017-02-24 2022-01-11 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment B as a carrier
BR112019026192B1 (en) * 2017-06-10 2022-05-10 Inventprise, Llc Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
KR20200040812A (en) * 2017-08-16 2020-04-20 머크 샤프 앤드 돔 코포레이션 Pneumococcal conjugate vaccine preparation
US11389540B2 (en) * 2017-09-07 2022-07-19 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2019050815A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2019050813A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
BR112020004396A8 (en) * 2017-09-07 2023-01-31 Merck Sharp & Dohme PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES
BR112020004410A8 (en) 2017-09-07 2023-01-31 Merck Sharp & Dohme PROCESSES FOR THE FORMULATION OF PNEUMOCOCCAL POLYSACCHARIDES FOR CONJUGATION TO A CARRIER PROTEIN
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US12257295B2 (en) 2017-10-04 2025-03-25 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
AR114154A1 (en) 2017-12-06 2020-07-29 Merck Sharp & Dohme COMPOSITIONS INCLUDING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATES WITH PROTEIN AND METHODS OF USE OF THESE
WO2019152921A1 (en) * 2018-02-05 2019-08-08 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
KR102486891B1 (en) 2018-02-05 2023-01-10 사노피 파스퇴르 인코포레이티드 Polyvalent pneumococcal polysaccharide-protein conjugate composition
AU2019256218A1 (en) 2018-04-18 2020-12-03 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
KR20210005158A (en) 2018-04-30 2021-01-13 머크 샤프 앤드 돔 코포레이션 Method for producing a capsular polysaccharide carrier protein conjugate to Streptococcus pneumoniae
CN112041435B (en) 2018-04-30 2024-05-31 默沙东有限责任公司 Method for providing a homogeneous solution of lyophilized mutant diphtheria toxin in dimethyl sulfoxide
JP7489324B2 (en) 2018-04-30 2024-05-23 メルク・シャープ・アンド・ドーム・エルエルシー Method for producing Streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from riospheres - Patent Application 20070233333
WO2019220304A1 (en) * 2018-05-14 2019-11-21 Tergene Biotech Pvt. Ltd. 15 valent pneumococcal polysaccharide conjugate vaccine
US11389519B2 (en) 2018-06-11 2022-07-19 Inventprise, Llc Virus-like particle conjugates
WO2020009462A1 (en) * 2018-07-06 2020-01-09 주식회사 유바이오로직스 Multivalent immunogenic composition comprising polysaccharide-protein conjugates, and vaccine comprising same for preventing disease caused by streptococcus pneumoniae
CN112673054A (en) * 2018-07-19 2021-04-16 葛兰素史密丝克莱恩生物有限公司 Process for preparing dried polysaccharides
KR20210093854A (en) * 2018-09-12 2021-07-28 아피니백스, 인크. polyvalent pneumococcal vaccine
CN113194987B (en) 2018-10-12 2024-11-08 生物E有限公司 Multivalent pneumococcal polysaccharide-protein conjugate vaccine
KR20240169145A (en) 2018-12-19 2024-12-02 머크 샤프 앤드 돔 엘엘씨 Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
MX2021014948A (en) * 2019-06-05 2022-01-24 Merck Sharp & Dohme Llc METHODS OF TREATING PATIENTS WITH AN IMMUNOGENIC COMPOSITION THAT PROTECTS AGAINST <i>S. PNEUMONIAE</i> SEROTYPE 29.
US20220233674A1 (en) * 2019-06-05 2022-07-28 Merck Sharp & Dohme Corp. An immunogenic serotype 35b pneumococcal polysaccharide-protein conjugate and conjugation process for making the same
WO2021010798A1 (en) * 2019-07-18 2021-01-21 (주)셀트리온 Immunogenic composition comprising multivalent streptococcus pneumoniae polysaccharide-protein conjugates
JP2022542316A (en) 2019-07-31 2022-09-30 サノフィ パスツール インコーポレイテッド Polyvalent pneumococcal polysaccharide-protein conjugate compositions and methods of use thereof
JP7630603B2 (en) 2020-08-10 2025-02-17 インベントプライズ・インコーポレイテッド Multivalent pneumococcal glycoconjugate vaccine containing the emerging serotype 24F
KR20220102871A (en) * 2021-01-14 2022-07-21 (주)셀트리온 The immunogenic composition comprising multivalent pneumococcal polysaccharide-protein conjugate
TW202245835A (en) 2021-02-04 2022-12-01 美商默沙東有限責任公司 Nanoemulsion adjuvant composition for pneumococcal conjugate vaccines
US20240390471A1 (en) 2023-05-18 2024-11-28 Merck Sharp & Dohme Llc Compounds and adjuvant formulations useful in pneumococcal vaccines

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
MY133981A (en) * 2000-06-29 2007-11-30 Smithkline Beecham Biologicals S A Vaccine composition
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
WO2005120563A2 (en) * 2004-06-04 2005-12-22 Pharmexa Inc. Induction of an immune response against streptococcus pneumoniae polysaccharides
CN1660881A (en) * 2005-01-12 2005-08-31 北京万赛生物医药技术发展有限公司 New type molecules of immunization stimulus and preparation method
KR102611449B1 (en) * 2005-04-08 2023-12-06 와이어쓰 엘엘씨 Multivalent pneumococcal polysaccharide-protein conjugate composition
ES2662651T3 (en) * 2005-06-27 2018-04-09 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2007053781A2 (en) * 2005-11-01 2007-05-10 Novartis Ag Compositions with antigens adsorbed to calcium phosphate
SI1962899T1 (en) * 2005-12-22 2011-11-30 Glaxosmithkline Biolog Sa Pneumococcal polysaccharide conjugate vaccine
JP2009520771A (en) * 2005-12-23 2009-05-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Conjugate vaccine
US20070253985A1 (en) * 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
PL3406635T3 (en) 2007-03-23 2022-08-22 Wyeth Llc Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
ES2626662T3 (en) * 2007-06-26 2017-07-25 Glaxosmithkline Biologicals S.A. Vaccine comprising capsular polysaccharide conjugates of Streptococcus pneumoniae
CN101590224A (en) 2009-06-30 2009-12-02 广州精达医学科技有限公司 High-efficiency 14-valent pneumococcal conjugate vaccine

Also Published As

Publication number Publication date
SG183199A1 (en) 2012-09-27
BR112012019757B1 (en) 2020-11-17
CL2012002195A1 (en) 2012-11-30
PH12012501559A1 (en) 2012-10-22
ZA201205737B (en) 2013-04-24
PE20121698A1 (en) 2012-12-11
WO2011100151A1 (en) 2011-08-18
JP2014012720A (en) 2014-01-23
MX2012009206A (en) 2012-08-23
MY159984A (en) 2017-02-15
CA2788680A1 (en) 2011-08-18
TN2012000377A1 (en) 2014-01-30
AU2011216095A1 (en) 2012-08-09
AR116043A2 (en) 2021-03-25
US8192746B2 (en) 2012-06-05
RU2012138368A (en) 2014-03-20
MA34051B1 (en) 2013-03-05
CN102858365A (en) 2013-01-02
AR080122A1 (en) 2012-03-14
TW201136603A (en) 2011-11-01
CA2788680C (en) 2014-12-16
ECSP12012100A (en) 2013-03-28
NZ601711A (en) 2014-03-28
EP2533805A4 (en) 2013-08-28
KR101538535B1 (en) 2015-07-22
UA106115C2 (en) 2014-07-25
AU2011216095B2 (en) 2013-07-18
US20110195086A1 (en) 2011-08-11
IL221283A0 (en) 2012-10-31
US20120301502A1 (en) 2012-11-29
KR20120114345A (en) 2012-10-16
BR112012019757B8 (en) 2023-04-25
JP2013518891A (en) 2013-05-23
BR112012019757A2 (en) 2016-05-10
EP2533805A1 (en) 2012-12-19

Similar Documents

Publication Publication Date Title
IL221283A0 (en) 15-valent pneumococcal polysaccharide - protein conjugate vaccine composition
PL2932980T3 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
GB201003924D0 (en) Immunogenic composition
GB0913681D0 (en) Immunogenic composition
IL215389A0 (en) Pneumococcal vaccine and uses thereof
IL223206A0 (en) Vaccine formulations
GB201015132D0 (en) Vaccine composition
ZA201209739B (en) Levocarrimycin,pharmaceutical compositions,preparation methods and uses thereof
PT2402032T (en) Immunogenic composition
IL242592A (en) Immunogenic compositions
HUE044772T2 (en) Immunogenic composition
PT2640417T (en) Multivalent vaccine for filariasis
EP2515940A4 (en) Immunogenic compositions and related methods
IL214127A0 (en) Vaccine compositions
EP2252326A4 (en) Vaccine compositions
EP2640418A4 (en) Immunogenic compositions
IL214211A0 (en) Stable vaccine compositions and methods for preparing the same
GB0913680D0 (en) Immunogenic composition
IL220308A0 (en) Vaccine compositions
GB0801122D0 (en) Vaccine composition
HK1172562A (en) 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
ZA201301908B (en) Immunogenic compositions
AU2013360597B2 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
GB201003918D0 (en) Immunogenic composition
GB0802326D0 (en) Vaccine Composition